Business Description
DuoGenic StemCells Corp
ISIN : TW0007607004
Total Employee Number:
23Description
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.24 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.44 | |||||
Debt-to-EBITDA | -1.13 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 7.12 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 39.6 | |||||
3-Year EBITDA Growth Rate | 14.5 | |||||
3-Year EPS without NRI Growth Rate | 11.4 | |||||
3-Year FCF Growth Rate | 28.1 | |||||
3-Year Book Growth Rate | -15.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 42.53 | |||||
9-Day RSI | 47.39 | |||||
14-Day RSI | 47.98 | |||||
3-1 Month Momentum % | -19.46 | |||||
6-1 Month Momentum % | -30.31 | |||||
12-1 Month Momentum % | 37.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.24 | |||||
Quick Ratio | 2.15 | |||||
Cash Ratio | 1.88 | |||||
Days Inventory | 265.59 | |||||
Days Sales Outstanding | 53.31 | |||||
Days Payable | 26.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.2 | |||||
Shareholder Yield % | -13.08 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 76.33 | |||||
Operating Margin % | -124.65 | |||||
Net Margin % | -127.48 | |||||
EBITDA Margin % | -94.84 | |||||
FCF Margin % | -89.28 | |||||
OCF Margin % | -89.28 | |||||
ROE % | -91.78 | |||||
ROA % | -40.41 | |||||
ROIC % | -53.91 | |||||
3-Year ROIIC % | 116.57 | |||||
ROC (Joel Greenblatt) % | -130.69 | |||||
ROCE % | -82.52 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 21.96 | |||||
PB Ratio | 9.59 | |||||
Price-to-Tangible-Book | 9.68 | |||||
EV-to-EBIT | -18.66 | |||||
EV-to-EBITDA | -24.28 | |||||
EV-to-Revenue | 23.02 | |||||
EV-to-FCF | -26.09 | |||||
Price-to-GF-Value | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 15.28 | |||||
| Price-to-Net-Cash | 22.18 | |||||
Earnings Yield (Greenblatt) % | -5.36 | |||||
FCF Yield % | -3.67 |
DuoGenic StemCells Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DuoGenic StemCells Corp Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on DuoGenic StemCells Corp
No articles.